Amgen Inc. on Monday announced positive results from late-stage trials that treated colorectal cancer patients with Neulasta, a drug that boosts white blood cell counts.
In the phase three study, the drug was shown to reduce the incidence of febrile neutropenia, a condition of low white blood cell counts accompanied by a fever. The Thousand Oaks company said in a statement that the drug reduced occurrence of the condition by more than half.
“In addition to providing new data on Neulasta, we believe (the study) will provide valuable information to the oncology community on commonly-used chemotherapy regimens,” said Sean Harper, executive vice president of R&D at Amgen, in the statement.
Neulasta was first approved for some uses in patients with low white blood cell count in 2002. Last year, the drug accounted for more than $4 billion in sales for the company.
Shares gained $2.17, or 2.6 percent, to close at $85.59 on the Nasdaq.